EU Approval For Movetis' Resolor Validates Its Targeted Strategy in GI Disorders

This article was originally published in The Pink Sheet Daily

23 Oct 2009
News

The Pink Sheet Daily pinkeditor@informa.com

Executive Summary

The Belgian GI specialist's approval for its lead constipation drug illustrates the virtues of seeking out smaller, more targeted patient populations.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS068651

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS068651

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

EU Approval For Movetis' Resolor Validates Its Targeted Strategy in GI Disorders

News

Executive Summary

Related Content

Deals Of The Week: Shire/Janssen, Pfizer/SFJ Pharma, AstraZeneca/IMS Health

Best of the IN VIVO Blog, (01/2010)

Best of the IN VIVO Blog, (01/2010)

Pharma's R&D Heartburn Spells Opportunity for GI-Focused Biotechs

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert